(S034) Do Sociodemographic Factors Influence Outcome in Prostate Cancer Patients Treated With External Beam Radiation Therapy (EBRT)? 

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

To determine if there is an influence of sociodemographic factors on biochemical control (bNED) and overall survival (OS) in prostate cancer (CaP).

Avielle Y. Movsas, Ramy Ibrahim, MD, Mohamed A. Elshaikh, MD, Lois Lamerato, PhD, Mei Lu, PhD, Alexandra Sitarik, MS, Deepak Pradhan, MD, Eleanor M. Walker, MD, Hans Stricker, MD, Svend O. Freytag, PhD, Indrin Chetty, PhD, Benjamin Movsas, MD, Farzan Siddiqui, MD, PhD; Henry Ford Hospital

Objectives: To determine if there is an influence of sociodemographic factors on biochemical control (bNED) and overall survival (OS) in prostate cancer (CaP).

Methods: CaP patients treated with definitive EBRT ± hormone therapy (HT) from 1997–2006 were analyzed. Patient demographics, treatment (Tx), and clinical outcomes were obtained from electronic medical records. Median household income (mHHI) at the census block group level was obtained from the 2000 census data. Data on disease and Tx parameters included Gleason score, pre-Tx prostate-specific antigen (PSA), T-stage, year of Tx, EBRT dose and technique, and use of HT. Patients were categorized as having low-, intermediate-, or high-risk disease. Sociodemographic factors included age, race, marital status, and mHHI. Biochemical failure was defined as nadir PSA + 2 ng/mL. OS was based on death from any cause.

Results: A total of 788 consecutive patients were studied, with a median follow-up of 7 years. African Americans (AAs) constituted 48% of the patients, while 46% of patients were white and 6% was other. Whites had an average mHHI of $59,235 compared with $36,917 for AAs (P < .001). After multivariable modeling, only radiation dose was predictive for bNED or OS. For biochemical failure, compared with radiation dose < 70 Gy, the hazard ratio (HR) was 0.69 (95% confidence interval [CI], 0.49–0.98) for 70–74 Gy and 0.48 (95% CI, 0.31–0.74) for ≥ 75 Gy; for mortality, the HR was 0.67 (95% CI, 0.50–0.89) for 70-74 Gy and 0.62 (95% CI, 0.43–0.89) for ≥ 75 Gy. No sociodemographic factors were predictive of either outcome.

Conclusions: This analysis suggests that sociodemographic factors are not prognostic in determining outcome in prostate cancer, as long as patients have access to current standards of care. Rather, only a treatment factor-the radiation dose-predicted for bNED and OS.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content